Exagen Inc. (FRA:E08A)
Germany · Delayed Price · Currency is EUR | Market Cap | 97.02M -29.8% |
| Revenue (ttm) | 59.31M +20.6% |
| Net Income | -17.49M |
| EPS | -0.76 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 3.980 |
| Previous Close | 3.940 |
| Day's Range | 3.980 - 3.980 |
| 52-Week Range | 2.260 - 10.200 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About Exagen
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CT... [Read more]
Financial Performance
In 2025, Exagen's revenue was $66.58 million, an increase of 19.65% compared to the previous year's $55.64 million. Losses were -$19.95 million, 32.0% more than in 2024.
Financial numbers in USD Financial StatementsNews
Roth starts Exagen at Buy, notes biomarker testing outperformance
Roth Capital analyst Max Masucci initiated coverage of Exagen (XGN) with a Buy rating and $8 price target Exagen’s autoimmune testing portfolio, headlined by its AVISE CTD test, faces no…
Exagen initiated with a Buy at Roth Capital
Roth Capital initiated coverage of Exagen (XGN) with a Buy rating and $8 price target
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, mor...
Exagen price target lowered to $8 from $9 at BTIG
BTIG lowered the firm’s price target on Exagen (XGN) to $8 from $9 and keeps a Buy rating on the shares. The company delivered a 5% revenue beat in Q1…
Exagen reports Q1 EPS (17c), consensus (25c)
Reports Q1 revenue $17.31M, consensus $16.41M. “First quarter results establish a solid start to 2026, reflecting our team’s disciplined execution and effective revenue cycle management,” said John Ab...
Exagen backs FY26 revenue view $70M-$73M, consensus $71.27M
The company said, “The Company continues to expect full-year 2026 revenue of $70 million to $73 million.”
Exagen Earnings Call Transcript: Q1 2026
Record Q1 2026 revenue grew 12% year-over-year, with gross margin at 59% and improved profitability. Test volume and ASP both increased, and full-year guidance was reaffirmed. Commercial expansion and innovation continue to drive growth.
Exagen Earnings release: Q1 2026
Exagen released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Exagen Quarterly report: Q1 2026
Exagen has published its Q1 2026 quarterly earnings report on May 11, 2026.
Exagen Slides: Q1 2026
Exagen has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Exagen Inc. Reports First Quarter 2026 Results
CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026,...
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026...
Exagen Proxy statement: Proxy filing
Exagen filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Exagen Proxy statement: Proxy filing
Exagen filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Exagen price target lowered to $8 from $10 at Canaccord
Canaccord lowered the firm’s price target on Exagen (XGN) to $8 from $10 and keeps a Buy rating on the shares. The firm updated its model ahead of Q results…
Exagen price target lowered to $10 from $12 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Exagen (XGN) to $10 from $12 and keeps a Buy rating on the shares as the story has not played out as the…
Exagen price target lowered to $10 from $15 at Canaccord
Canaccord lowered the firm’s price target on Exagen (XGN) to $10 from $15 and keeps a Buy rating on the shares. The firm noted they reported inline Q4 results and…
Exagen price target lowered to $10 from $15 at KeyBanc
KeyBanc lowered the firm’s price target on Exagen (XGN) to $10 from $15 and keeps an Overweight rating on the shares. The firm notes the company posted Q4 earnings in…
Exagen price target lowered to $9 from $10 at BTIG
BTIG analyst Mark Massaro lowered the firm’s price target on Exagen (XGN) to $9 from $10 and keeps a Buy rating on the shares. Q4 was in line with the…
Exagen Earnings Call Transcript: Q4 2025
Record 2025 revenue grew nearly 20% to $66.6M, driven by 11% test volume growth and higher ASP. 2026 guidance targets $70–$73M revenue, with continued volume and ASP gains, and breakeven expected at ~$80M run rate, likely in 2027.
Exagen Annual report: Q4 2025
Exagen has published its Q4 2025 annual report on March 10, 2026.
Exagen Earnings release: Q4 2025
Exagen released its Q4 2025 earnings on March 10, 2026, summarizing the period's financial results.
Exagen Slides: Q4 2025
Exagen has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 10, 2026.
Exagen reports Q4 EPS (20c), consensus (19c)
Reports Q4 revenue $16.631M, consensus $16.57M. “Exagen (XGN) is committed to improving care for autoimmune disease, delivering clarity for patients and confidence for clinicians,” said John Aballi, P...
Exagen sees FY26 revenue $70M-$73M, consensus $73.84M
The Company expects full-year 2026 revenue of $70 million to $73 million.